Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intravitreal bevacizumab.
A patient presented with subfoveal choroidal neovascularization associated with angioid streaks and was treated with three intravitreal injections of off-label bevacizumab (1.25 mg) in the right eye. Visual acuity improved from 20/70 to 20/20 and remained at this level for 32 months. In certain patients with choroidal neovascularization from angioid streaks, intravitreal bevacizumab may produce normalization of visual acuity and macular anatomy for an extended period of time.
Kovach
Jaclyn L
JL
Bascom Palmer Eye Institute, Retina Center at Naples, 311 9th Street North, #100, Naples, FL 34102, USA.
Schwartz
Stephen G
SG
Hickey
Marcela
M
Puliafito
Carmen A
CA
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000793:Angioid Streaks / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab